Overview
Postlingual non-syndromic genetic deafness refers to a group of hereditary hearing loss conditions that manifest after the development of speech and language skills (postlingual onset), without any other associated clinical features affecting other organ systems (non-syndromic). Unlike prelingual forms of deafness that are present at birth or in early infancy, postlingual forms typically begin in childhood, adolescence, or adulthood, after the individual has already acquired spoken language. The hearing loss is sensorineural in most cases, resulting from dysfunction of the inner ear (cochlea) or the auditory nerve, though some forms may involve conductive or mixed hearing loss. The condition exclusively affects the auditory system. Hearing loss may be progressive, starting as mild high-frequency loss and gradually worsening over years to decades, or it may present as a more sudden decline. The degree of hearing impairment can range from mild to profound. Because language has already been acquired before onset, affected individuals generally retain speech abilities, though speech clarity may decline over time without intervention. Multiple genes have been implicated, including those encoding structural proteins of the cochlea, ion channels, and components of the tectorial membrane. Well-known genes associated with postlingual forms include DFNA genes (autosomal dominant loci) such as those involving WFS1, KCNQ4, COCH, TECTA, and MYO6, among many others. Autosomal recessive and X-linked forms also exist but are less commonly postlingual. There is currently no curative treatment for postlingual non-syndromic genetic deafness. Management focuses on audiological rehabilitation, including hearing aids for mild to moderate loss and cochlear implantation for severe to profound hearing loss. Early identification through genetic testing and audiometric monitoring can help guide timely intervention. Genetic counseling is recommended for affected individuals and their families to clarify the inheritance pattern, recurrence risk, and prognosis specific to the causative gene variant.
Also known as:
Variable
Can be inherited in different ways depending on the underlying gene
Childhood to adulthood
Can begin any time from childhood through adulthood
Treatments
No FDA-approved treatments are currently listed for Postlingual non-syndromic genetic deafness.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Postlingual non-syndromic genetic deafness at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Postlingual non-syndromic genetic deafness.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Postlingual non-syndromic genetic deafness.
Community
No community posts yet. Be the first to share your experience with Postlingual non-syndromic genetic deafness.
Start the conversation →Latest news about Postlingual non-syndromic genetic deafness
No recent news articles for Postlingual non-syndromic genetic deafness.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Postlingual non-syndromic genetic deafness
What is Postlingual non-syndromic genetic deafness?
Postlingual non-syndromic genetic deafness refers to a group of hereditary hearing loss conditions that manifest after the development of speech and language skills (postlingual onset), without any other associated clinical features affecting other organ systems (non-syndromic). Unlike prelingual forms of deafness that are present at birth or in early infancy, postlingual forms typically begin in childhood, adolescence, or adulthood, after the individual has already acquired spoken language. The hearing loss is sensorineural in most cases, resulting from dysfunction of the inner ear (cochlea)
At what age does Postlingual non-syndromic genetic deafness typically begin?
Typical onset of Postlingual non-syndromic genetic deafness is childhood to adulthood. Age of onset can vary across affected individuals.